Sou Hu Cai Jing·2025-11-01 23:04Core Viewpoint - Spring Medical (688236) has shown significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational performance and potential investment opportunities. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 756 million yuan, a year-on-year increase of 48.75% [2] - The net profit attributable to shareholders reached 192 million yuan, reflecting a substantial year-on-year growth of 213.21% [2] - The net profit for the third quarter alone was 77.06 million yuan, marking a remarkable increase of 531.12% compared to the same period last year [5] Shareholder and Stock Information - As of September 30, 2025, the number of shareholders increased to 6,149, up by 4.11% from June 30, 2025 [3] - The average number of shares held per shareholder decreased from 48,800 to 46,900, with an average holding value of 1.1684 million yuan [3] Dividend and Corporate Governance - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares (including tax), totaling approximately 80.26 million yuan, which represents 41.90% of the net profit [3][5] - The board has approved a proposal to abolish the supervisory board, transferring its functions to the audit committee of the board, pending shareholder approval [3][5] Asset Impairment - For the first three quarters of 2025, the company recognized an asset impairment provision totaling 45.71 million yuan, primarily due to bad debt losses and inventory write-downs [3]